Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.
about
HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategiesClinical significance of HIV-1 coreceptor usage.The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approachProlonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencingChallenges and opportunities in estimating viral genetic diversity from next-generation sequencing dataReconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence DataHIV-1 drug resistance and resistance testing.Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropismFrequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing dataSensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy"Deep" sequencing accuracy and reproducibility using Roche/454 technology for inferring co-receptor usage in HIV-1.Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis.Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.A comparison of parallel pyrosequencing and sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsA genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patientsTargeted deep sequencing of HIV-1 using the IonTorrentPGM platformUse of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patientsRisk of breast cancer with CXCR4-using HIV defined by V3 loop sequencingHIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].A diagnostic HIV-1 tropism system based on sequence relatedness.Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.Individualization of antiretroviral therapy.Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection.Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNA.Slow immunological progression in HIV-1 CRF07_BC-infected injecting drug users.HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.Determination of HIV tropism and its use in the clinical practice.Deep sequencing: becoming a critical tool in clinical virology.HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.Frequency of coreceptor tropism in PBMC samples from HIV-1 recently infected blood donors by massively parallel sequencing: the REDS II study.Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: WeeResults of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
P2860
Q26825087-30ACD483-17F9-4CFF-B391-23286F793E3DQ27691426-A9848B7E-F5F9-4ACF-8C48-F3F971BA1332Q28476558-F562AE86-370D-4743-BEDE-281A38E34403Q28484064-E184C1FA-EB7F-4157-8463-490CC7B7C661Q28727944-33C59419-FFF1-4329-94DE-CF92F6EC86BBQ29394572-71495C72-7C2C-4E39-8151-735BC6B9823BQ30245693-E7C60C45-59AD-46AF-A6CA-711F856D8FE0Q31026698-C7BEB1BF-7296-4987-B09E-8532399D25CBQ31044033-CA279A43-133E-4553-89D6-BFB5008061DDQ33622927-802B24B3-6FF9-40D5-B319-0BD68C3CEB94Q33721466-A1900726-9896-4FE5-8EC6-2A5500E590F6Q33800017-F7FF71FD-0C13-4477-B469-E9AE8D3BF6B8Q33899080-5DCE338A-77E2-4021-9160-54CB59402EB2Q33951977-91070903-E929-414B-AF19-62EFAE64601DQ34062608-5CDABFC8-B695-411A-9EA5-7C71AFCD35C4Q34280466-6C4BFBB5-1FA9-4F91-A6C7-EAE9098F8C6FQ34431102-65C63B51-EF88-483D-B0AD-8B2804B20FF5Q34451254-84B5192E-E2B4-4F49-90E3-0253798DE867Q34482589-39940E30-EB85-4BD7-B4EF-1FFA62CA688BQ34508492-28D66F3F-BADA-47C0-9141-7F635FB48114Q34674367-C1B76A71-6B37-4953-AE5A-E35B4CA06706Q34716813-C2CB3EF6-E776-4FEA-A0AC-3ABFC5748CEBQ34983107-1F7D8E2C-C986-4B3A-9573-6F44B8204455Q35806266-504DA7A4-42B6-4AB2-A31B-DF8DDD052E05Q36441423-0208D4A8-39A1-4F73-9BEE-D60647963BAAQ36795929-8F4FC4B4-5455-4015-A7DC-7F40BA4AE6D2Q36826759-8B34CB9E-1E0A-4438-80F9-AF8F4B84B2F9Q36936363-073F3D88-0ADC-4D14-B01F-0B74C9DE3A7CQ37405921-94CCC1A2-0914-4447-BDA7-1D1F413DC295Q37433787-7CCBE7AB-A2D2-4A9F-9B04-65800FEECF83Q37525642-E94627FC-7AE6-40AD-8210-358CCE091CDDQ37547823-7E340622-B3C4-44A7-8FFD-1DC2D8EB1C1DQ38160078-88ECB5F4-3E49-41A0-A03D-E92B6983F4EBQ38226696-A13D32D0-2829-455B-95E3-853CEBE895CEQ38390465-AF104FD4-FD93-415E-9AD2-A079197F3C13Q38398452-8CE1C348-E1A3-40FB-8045-CCC7E8B79FDCQ38887171-47B66887-32BF-4636-B7D0-2324C8936420Q39351260-BFCB2951-C0B0-42C7-A9EC-D5D0E5C18B6AQ39352442-06E6CF3E-B143-47A8-BCBB-FB52E89903A2Q39536633-F6BFE711-B408-4D82-A87A-29FB1C86F1D0
P2860
Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@en
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@nl
type
label
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@en
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@nl
prefLabel
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@en
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@nl
P2093
P1476
Improved detection of CXCR4-us ...... o plasma RNA and proviral DNA.
@en
P2093
Alexander Thielen
Andrew J Low
Andrew Moores
Brian Wynhoven
Christopher Glascock
Conan Woods
Dennison Chan
Mark A Jensen
P Richard Harrigan
Winnie Dong
P304
P356
10.1097/QAI.0B013E3181D0558F
P407
P577
2010-08-01T00:00:00Z